Screener
Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001819790-26-000019
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Capitalized research and development | 7,959 | 21,734 |
| Charitable contributions | 27,692 | 8,842 |
| Intangible assets | 3,575 | 3,658 |
| Stock-based compensation | 6,877 | 4,760 |
| Accruals | 13,638 | 6,764 |
| Operating lease liability | 4,361 | 151 |
| Other, net | 124 | 169 |
| Total deferred tax assets before valuation allowance | 112,673 | 88,397 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets of $6.88M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets increased by 44.5% year-over-year, from $4.76M to $6.88M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets has grown at a 139.6% compound annual growth rate (CAGR), from $87K to $6.88M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude